¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"acute cellular rejection"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® rejection ÇÑ±Û °ÅºÎ
¼³¸í   
  ¾î¶² °³Ã¼ÀÇ Á¶Á÷À» ´Ù¸¥ °³Ã¼¿¡ À̽ÄÇßÀ» ¶§ ±×°ÍÀ» ¹èÁ¦Çϴ »ýü¹ÝÀÀ. °³Ã¼°£¿¡ À̽ļö¼úÀ» Çϸé Ã³À½ 7~10ÀÏ Á¤µµ´Â Ç÷¾×°ø±Þµµ È¸º¹µÇ°í º°´Ù¸¥ ÀÌ»óÀ» ¹ß°ßÇÏÁö ¸øÇÏÁö¸¸, ±× ÈÄ¿¡ ±«»ç°¡ »ý±ä´Ù. ±× ¶§¹®¿¡ Àå±âÀ̽ĠÈÄ¿¡ °¢Á¾ Áõ»óÀÌ ¹ß»ýÇÏ¿© À̽ļö¼úÀÌ ½ÇÆÐ·Î µ¹¾Æ°¡±â ½±´Ù. »ç¶÷ÀǠü³»¿¡ ÀÌÁ¾ÀÇ Á¶Á÷ÀÌ µé¾î°¡¸é ±×¿¡ ´ëÇØ Ç×ü°¡ ¸¸µé¾îÁø´Ù. À̴ Ç÷¾× ¼ÓÀÇ ¸²ÇÁ±¸°¡ ±× ÀÌÁ¾Á¶Á÷¿¡ Á¢ÃËÇÏ¿© È°¼ºÈ­µÈ »óÅ¿¡¼­ ¸²ÇÁÀý·Î µÇµ¹¾Æ¿Í¼­ °Å±â¼­ Ç×ü¸¦ ¸¸µå´Â °ÍÀ¸·Î »ý°¢µÇ°í ÀÖ´Ù. ÀÌ Ç×ü´Â ¼¼Æ÷¼ºÇ×ü¿Í Ã¼¾×¼ºÇ×ü·Î ³ª´©¾îÁö¸ç ÀÌ ¾çÀÚÀÇ °øµ¿ÀÛ¿ë¿¡ ÀÇÇØ °ÅºÎ¹ÝÀÀÀÌ »ý±â´Â °ÍÀ¸·Î º¸ÀδÙ. À̴ °³Ã¼¹æÀ§¹ÝÀÀÀ̶ó°íµµ ÇÒ ¼ö ÀÖÁö¸¸ À̽ÄÁ¶Á÷ÀÇ Ç÷°üÀº ±×°ÍµéÀÇ ÀÛ¿ëÀ¸·Î ³»ÇǼ¼Æ÷°¡ »óÇÏ¿© Ç÷ÀüÀ» Çü¼ºÇϹǷΠÇ÷ÇàÀÌ µÎÀýµÈ´Ù. ±× ¶§¹®¿¡ ±«»ç°¡ »ý±â°í ±«»çÁ¶Á÷Àº Ã¼¿Ü·Î ¹èÃâµÈ´Ù. °ÅºÎ¹ÝÀÀÀº À̽ÄÁ÷ÈÄ¿¡ »ý±â´Â °Í, ¼öÁÖ¿¡¼­ ¼ö°³¿ù ÈÄ¿¡ ºñ±³Àû ±Þ¼ºÀ¸·Î »ý±â´Â °Í, ¼ö³â ÈÄ¿¡ ¼­¼­È÷ »ý±â´Â °ÍÀÌ ÀÖ´Ù. Àå±â À̽Ľÿ¡´Â ÀÌ ¹ÝÀÀÀ» ¾ïÁ¦Çϱâ À§ÇØ ¸é¿ª¾ïÁ¦Á¦³ª ºÎ½Å°ÑÁúÈ£¸£¸óÀ» Åõ¿©ÇÑ´Ù. 
¿µ¹® acute hepatitis ÇÑ±Û ±Þ¼º°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ °£¿¡ »ý±â´Â ±Þ¼º¿°Áõ. ±Þ¼º°£¿°À̶õ °£¿°¹ÙÀÌ·¯½º(AÇü-BÇü-ºñAºñBÇü)¿¡ ÀÇÇØ¼­ °£¿¡ »ý±â´Â ±Þ¼º¿°ÁõÀ» º´¸íÀ¸·Î À̸£´Â ¸»·Î, À̴ ±× °¨¿°¾ç½Ä¿¡ ¼öÇ÷ ÈÄ¿¡ ¹ß»ýÇϴ ¼öÇ÷ÈÄ °£¿°°ú, °¨¿°°æ·Î¸¦ ¾Ë ¼ö ¾ø´Â »ê¹ß¼º°£¿° ¹× Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༱°£¿°ÀÇ ¼¼°¡Áö À¯ÇüÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ¼öÇ÷ÈÄ °£¿°Àº ±× 95%°¡ ºñAºñBÇü°£¿°À̸砳ª¸ÓÁö°¡ BÇü °£¿°ÀÌ´Ù. »ê¹ß¼º °£¿°Àº AÇü °£¿°°ú BÇü °£¿°ÀÌ °¢°¢ 30%¸¦ ÀÌ·ç°í ³ª¸ÓÁö 40%´Â ºñAºñB°£¿°ÀÌ´Ù. Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༺°£¿°Àº °ÅÀǰ¡ AÇü°£¿°ÀÌÁö¸¸ ¶§·Î´Â ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾ÊÀº ÇüÀÇ °£¿°ÀÏ °æ¿ìµµ ÀÖ´Ù. ±Þ¼º°£¿°ÀÇ Áõ¼¼´Â ¸ÕÀú ¸öÀÌ ³ª¸¥ÇØÁö°í ¿Â¸ö¿¡ ±ÇۨÀ̠ã¾Æ¿À¸ç Á¶±×¸¶ÇÑ ÀÏ¿¡µµ °ð ÇǷθ¦ ´À³¢°Ô µÈ´Ù. ±×¸®°í ½Ä¿åºÎÁø-¹ß¿­-±¸ÅäÁõ-º¹Åë-¼³»ç µî, °¨±â³ª ±Þ¼ºÀ§Àå¿°¿¡ °É·ÈÀ» ¶§¿Í °°Àº Áõ¼¼ µîÀÌ ³ªÅ¸³­´Ù. µÚÀ̾î È²´ÞÁõ¼¼¸¦ º¸À̴µ¥, À̶§´Â ÃʱâÀÇ Áõ¼¼°¡ ¾à°£ °¡º­¿öÁø °Íó·³ ´À²¸Áö´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª È²´ÞÁõ¼¼°¡ ½ÉÇØÁö°í ÃʱâÀÇ Áõ¼¼µéÀÌ ´Ù½Ã ÁøÇàµÇ¸é À̶§´Â Àü°Ý¼º°£¿°ÀÌ µÉ À§ÇèÀÌ ÀÖ´Ù. °£¿° Áõ¼¼°¡ ½ÉÇÏÁö ¾Ê¾ÒÀ» °æ¿ì´Â È²´ÞÀÌ ´«¿¡ ¶çÁö ¾ÊÀº °æ¿ìµµ Àִµ¥ À̶§´Â ÁøÂûÀ» Çصµ °¨±â³ª ±Þ¼ºÀ§Ã¢ÀÚ¿°À¸·Î ÀÚÄ© ¿ÀÁøµÇ±â ½±´Ù. ¶Ç AÇü°£¿°Àº ¿­ÀÌ 38~39¡É±îÁö ¿À¸£°í Áõ¼¼°¡ °©Àڱ⠳ªÅ¸³ª´Â °ÍÀ̠Ư¡À̸砱޼ººñAºñBÇü°£¿°Àº Áõ¼¼°¡ ºñ±³Àû °¡º­¿î °ÍÀ̠Ư¡ÀÌ´Ù. ±Þ¼ºBÇü°£¿°ÀÇ Áõ¼¼´Â AÇü°£¿°°ú ±Þ¼ººñAºñBÇü°£¿°ÀÇ Áß°£ Á¤µµÀΠ°ÍÀÌ º¸ÅëÀÌ´Ù.
¿µ¹® acute appendicitis ÇÑ±Û ±Þ¼º¸·Ã¢ÀÚ²¿¸®¿°
¼³¸í   
  ¿Ü°úÀû Ã³Ä¡¸¦ ¿äÇϴ ¸·Ã¢ÀÚ²¿¸®(Ãæ¼ö)ÀÇ ±Þ¼º¿°ÁõÀ¸·Î¼­, º¸Åë ÇϺ¹ºÎÀÇ ¿À¸¥ÂÊ 1/4 ºÎÀ§¿¡¼­ÀÇ ÅëÁõÀ̠Ư¡À̸ç, ±¹¼Ò¾ÐÅë, ±ÙÀ°±äÀå ÇǺΰ¨°¢ÀÇ °ú¹Î µîÀ» ¼ö¹ÝÇÑ´Ù. ÀϹݵòµéÀÌ ¡°¸ÍÀå¿°¡±À̶ó°í Çϴ °ÍÀ¸·Î ¸ÍÀå¿°Àº ¸·Ã¢ÀÚÀÇ ¿°ÁõÀ¸·Î ±¸º°µÇ¾î¾ß ÇÑ´Ù. ¹ß¿­°ú ´ÙÇü¹éÇ÷±¸Áõ´Ù´Â ±¹¼Ò°¨¿°ÀÇ °á°úÀÌ´Ù. ¸·Ã¢ÀÚ²¿¸®ÀÇ À§Ä¡-À¯Âø»óÅÂ-²¿ÀÓ µî¿¡ ÀÇÇØ Áõ»ó°ú Â¡ÈĴ º¯µ¿µÈ´Ù.
¿µ¹® acute cholecystitis ÇÑ±Û ±Þ¼º¾µ°³¿°
¼³¸í   
  º¸Åë ¾µ°³ ÃⱸÀÇ Æó»ö¿¡ ÀÇÇÑ °ÍÀ̸ç, ¿°ÁõÀÇ Á¤µµ´Â °æµµÀÇ ºÎÁ¾À¸·ÎºÎÅÍ ±«Àú¿Í Ãµ°øÀ» ¼ö¹ÝÇϴ °¨¿°Áõ±îÁö ÀÖ´Ù.
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û »ç½º
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼º È£Èí±â ÁúȯÀ¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. 
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • allograft rejection
    µ¿Á¾À̽İźιÝÀÀ
  • cardiac rejection
    ½ÉÀåÀ̽İźιÝÀÀ
  • first-set rejection
    ÀÏÂ÷°ÅºÎ¹ÝÀÀ
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ¹ÝÀÀ
  • homograft rejection
    µ¿Á¾À̽İźιÝÀÀ
  • rejection
    1. °ÅºÎ, °ÅºÎ¹ÝÀÀ 2. °ÅÀý 3. Æó±â
  • rejection reaction
    °ÅºÎ¹ÝÀÀ
  • specimen rejection
    °Ëü°ÅÀý
  • cellular
    ¼¼Æ÷-
  • cellular adhesiveness
    ¼¼Æ÷ºÎÂø¼º
  • cellular aging
    ¼¼Æ÷³ëÈ­
  • cellular antibody
    ¼¼Æ÷Ç×ü
  • cellular cast
    ¼¼Æ÷¿øÁÖ
  • cellular cementum
    ¼¼Æ÷½Ã¸àÆ®Áú
  • cellular immunity
    ¼¼Æ÷¸é¿ª
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular type
    ¼¼Æ÷Çü
  • rejection
    °ÅºÎ
  • allograft rejection
    µ¿Á¾À̽İźÎ
  • rejection reaction
    °ÅºÎ¹ÝÀÀ
  • acute
    ±Þ¼º-
  • acute appendicitis
    ±Þ¼º¸·Ã¢ÀÚ²¿¸®¿°
  • acute pulmonary atelectasis
    ±Þ¼º¹«±âÆó
  • acute abdomen
    ±Þ¼ºº¹Áõ
  • acute cholecystitis
    ±Þ¼º¾µ°³¿°
  • acute acalculous cholecystitis
    ±Þ¼º¹«°á¼®¾µ°³¿°
  • acute emphysematous cholecystitis
    ±Þ¼º°ø±âÁõ¾µ°³¿°, ±Þ¼º°ø±âÁõ´ã³¶¿°
  • acute febrile episode
    ±Þ¼º¿­¼º¹ÝÀÀ
  • acute renal failure
    ±Þ¼ºÄáÆÏ±â´É»ó½Ç, ±Þ¼º½ÅºÎÀü(Áõ)
  • acute hepatitis
    ±Þ¼º°£¿°
  • acute transverse myelitis
    ±Þ¼ºÈ¾´Üô¼ö¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • allograft rejection
    µ¿Á¾À̽İźÎ
  • cardiac rejection
    ½ÉÀåÀ̽İźιÝÀÀ
  • first-set rejection
    ÀÏÂ÷°ÅºÎ
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ
  • homograft rejection
    µ¿Á¾ÀÌ½ÄÆí°ÅºÎ
  • rejection
    °ÅºÎ
  • rejection reaction
    °ÅºÎ¹ÝÀÀ
  • specimen rejection
    °Ëü°ÅÀý
  • transplant rejection
    À̽İźÎ
  • tubular rejection fraction ratio
    ÄáÆÏ´¢¼¼°ü°ÅºÎºÐȹ·ü
  • cellular adhesiveness
    ¼¼Æ÷ºÎÂø¼º
  • cellular aging
    ¼¼Æ÷³ëÈ­
  • cellular antibody
    ¼¼Æ÷Ç×ü
  • cellular
    ¼¼Æ÷-
  • cellular cartilage
    ¼¼Æ÷¿¬°ñ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
  • hypersensitivity, cellular
    ¼¼Æ÷¼º °ú¹Î¹ÝÀÀ
  • impaired cellular immunity
    ¼¼Æ÷¼º ¸é¿ªºÎÀü(á¬øààõØóæ¹ÝÕîï).
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ).
  • graft rejection, white
    ¹é»öÈ­ ÀÌ½ÄÆí°ÅºÎ (Ãʱ޼º)
  • homograft rejection
    µ¿Á¾ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ)(¡­°ÅºÎ¹ÝÀÀ).
  • homograft rejection
    µ¿Á¾ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ)(¡­ËÞÜúÚãëë).
  • immunologic rejection
    ¸é¿ªÇÐÀû °ÅºÎ.
  • immunological rejection
    ¸é¿ªÇÐÀû°ÅºÎ
  • rejection
    °ÅºÎ (ËÞÜú)
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • rejection reaction
    °ÅÀý(¹ÝÀÀ)(ËÞï¾Úãëë).
  • rejection reaction
    °ÅÀý(¹ÝÀÀ)(ËÞï¾Úãëë).
  • rejection, allograft
    µ¿Á¾À̽Ä(Æí)°ÅºÎ(¹ÝÀÀ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • allograft rejection
    µ¿Á¾À̽İźιÝÀÀ
  • allograft rejection
    µ¿Á¾À̽Ä[Æí]°ÅºÎ[¹ÝÀÀ]
  • allograft rejection =homograft r.
    µ¿Á¾À̽Ä(Æí) °ÅºÎ(¹ÝÀÀ).
  • first set rejection
    1Â÷°ÅºÎ(¹ÝÀÀ).
  • first set rejection
    ÀÏÂ÷°ÅºÎ(¹ÝÀÀ).
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ).
  • graft rejection, white
    ¹é»öÈ­ ÀÌ½ÄÆí°ÅºÎ (Ãʱ޼º)
  • homograft rejection
    µ¿Á¾ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ)(¡­ËÞÜúÚãëë).
  • homograft rejection
    µ¿Á¾ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ)(¡­°ÅºÎ¹ÝÀÀ).
  • immunologic rejection
    ¸é¿ªÇÐÀû °ÅºÎ.
  • immunological rejection
    ¸é¿ªÇÐÀû°ÅºÎ
  • rejection
    °ÅºÎ (ËÞÜú)
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • rejection reaction
    °ÅÀý(¹ÝÀÀ)(ËÞï¾Úãëë).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Cellular deficiency (Acallosal cerebrum)
    ¼¼Æ÷°áÇÌ (³úµéº¸°á¿©³ú)
    [¿¾ ¿ë¾î] ¼¼Æ÷°áÇÌ
  • Cellular granule
    ¼¼Æ÷°ú¸³
    [¿¾ ¿ë¾î] ¼¼Æ÷°ú¸³
  • Cellular process
    ¼¼Æ÷µ¹±â
    [¿¾ ¿ë¾î] ¼¼Æ÷µ¹±â
  • Cellular islands
    ¼¼Æ÷¼¶
    [¿¾ ¿ë¾î] ¼¼Æ÷µµ
  • Cellular connective tissue
    ¼¼Æ÷¼º°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ¼¼Æ÷¼º°áÇÕÁ¶Á÷
  • Cellular membrane
    ¼¼Æ÷¼º¸·
    [¿¾ ¿ë¾î] ¼¼Æ÷¼º¸·
  • Cellular cementum
    ¼¼Æ÷½Ã¸àÆ®Áú
    [¿¾ ¿ë¾î] ¼¼Æ÷¼º½Ã¸àÆ®Áú
  • Cellular layer
    ¼¼Æ÷ÆÇ
    [¿¾ ¿ë¾î] ¼¼Æ÷Ãþ
  • Cellular invagination
    ¼¼Æ÷ÇÔÀÔ
    [¿¾ ¿ë¾î] ¼¼Æ÷ÇÔÀÔ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immunological rejection
    ¸é¿ª °ÅºÎ(Øóæ¹ËÞÜú)
  • trnsplant rejection
    À̽ÄÁ¶Á÷ °ÅºÎ(ì¹ãÕðÚòÄËÞÜú)
  • acute porphyria
    ±Þ¼º(Ðáàõ) Æ÷¸£ÇǸ°Áõ (ñø)
  • acute serum
    ±Þä Ç÷û(Ðáóõúìôè)
  • acute test
    ´Ü·® µ¶¼º½ÃÇè (Ó¤ÕáÔ¸àõãËúÐ)
  • antibody dependent cellular cytotoxicity
    Ç×üÀÇÁ¸ÀÚ¸® ¼¼Æ÷¼º¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øààõá¬øàÔ¸àõ)
  • cellular immunity
    ¼¼Æ÷¸é¿ª(á¬øàØóæ¹)
  • cellular oncogene
    ¼¼Æ÷ ¾ÏÀ¯ÀüÀÚ(á¬øàäßë¶îîí­)
  • cellular respiration
    ¼¼Æ÷È£Èí(á¬øàû¼ýå)
  • cellular retinol-binding protein
    ¼¼Æ÷(á¬øà) ·¹Æ¼³î°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • high cellular component
    °í¼¼Æ÷±¸¼º¼ººÐ
  • rejection
    °ÅÀý, °ÅºÎ, ±â°¢
  • transplant rejection
    À̽İźÎ
  • acute
    ±Þ¼º, ¿¹¸®ÇÑ
  • acute abdomen
    ±Þ¼ºº¹Áõ
  • acute angle
    ¿¹°¢
  • acute stage
    ±Þ¼º±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AML Acute Myelogenous Leukemia
  Morphologic Classification(FABºÐ·ù)
   &n...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
CR calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio...
AML acute monocytic leukemia; acute mucosal lesion; acute myeloblastic leukemia; acute myelocytic leukem...
AR absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ACR Acute cellular rejection
AR Acute Rejection
ARE Acute rejection episodes
AVR Acute vascular rejection
CR Chronic rejection
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute rejection vasculitis
    ±Þ¼º °ÅºÎ Ç÷°ü¿°
    ÀÌ½Ä ÈÄ ¸î °³¿ù ³»¿¡ ³ªÅ¸³ª°Å³ª ¸é¿ª¾ïÁ¦¿ä¹ýÀ» Áß´ÜÇßÀ» ¶§ ¹ß»ýÇÒ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ È¯ÀÚ´Â ÀÌ½Ä Àå±âÀÇ ±â´ÉÀå¾Ö°¡ ÀÌ½Ä ¼ö¼ú ÈÄ °©Àڱ⠳ªÅ¸³ª¼­ Áö¼Ó¼ºÀ» º¸ÀÌ¸ç °í´ÜÀ§ÀÇ ¸é¿ª¾ïÁ¦¿ä¹ý¿¡ ÀÇÇØ¼­µµ Àß Ä¡À¯µÇÁö ¾Ê´Â´Ù.
  • acute cellular rejecion
    ±Þ¼º ¼¼Æ÷¼º °ÅºÎ
    ÀϹÝÀûÀ¸·Î ÀÌ½Ä ÈÄ ¼ö °³¿ù ³»¿¡ ¹ß»ýÇϸç Ç÷û Å©·¹¾ÆÆ¼´ÑÄ¡°¡ »ó½ÂÇÏ°í ±Þ¼º ½ÅºÎÀüÀÇ ÀÓ»óÁõ»óÀ» µ¿¹ÝÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â °£Áú³» ´ÜÇÙ¼¼Æ÷ ħÀ±ÀÌ ¸Å¿ì °­ÇÏ°Ô ³ªÅ¸³ª¸ç, ºÎÁ¾ ¹× °æµµÀÇ °£Áú³» ÃâÇ÷À» º¸À̴µ¥ »ç¶÷ÀÇ °æ¿ì ´ÜÇÙ¼¼Æ÷´Â ÁÖ·Î Áß°£ Å©±â¿Í ÀÛÀº ¸²ÇÁ±¸·Î ±¸¼ºµÇ¾î ÀÖ°í dzºÎÇÑ È£¿°±â¼º ¼¼Æ÷Áú°ú ¼öÆ÷¼º ÇÙÀ» °¡Áø ¼Ò¼öÀÇ ÇüÁú¼¼Æ÷ ħÀ±µµ º¼ ¼ö ÀÖ´Ù.
  • allogenic rejection
    µ¿Á¾ ÀÌ½Ä °ÅºÎ
    µ¿Á¾ ÀÌ½ÄÆíÀÌ »ýÂøÇÏ´Â ÀÏÀÌ ¾øÀÌ °ÅºÎ´çÇØ¹ö¸®´Â °Í. ÀÌ½ÄÆí°ú °³Ã¼ »çÀÌÀÇ Á¶Á÷ ÀûÇÕ¼º Ç׿øÀÌ ´Ù¸£¸é À̵éÀÇ Ç׿ø¿¡ ´ëÇÑ ¼÷ÁÖÀÇ ¸é¿ª¹ÝÀÀÀÌ ¹æ¾Æ¼è°¡ µÇ¾î ÀÌ½ÄÆíÀÇ ÆÄ±«, Áï ÀÌ½Ä °ÅºÎÀÇ Çö»óÀÌ ¹ß»ýÇÑ´Ù. °ÅºÎÀÇ ÁÖ¿ªÀ» ÇØ³»´Â °ÍÀº ¼¼Æ÷¼º ¸é¿ªÀ̶ó°í ÇÑ´Ù.
  • complete rejection
    ÀüÀûÀÎ °ÅºÎ
  • first set rejection
    ÀÏÂ÷ °ÅºÎ, ÀÏÂ÷ °ÅºÎ ¹ÝÀÀ
    Á¦ 1ȸ°ÀÇ µ¿Á¾ À̽Ŀ¡ ÀϾ´Â °ÅºÎ ¹ÝÀÀÀÇ ¾ç½ÄÀÌ¸ç ºÎÀûÇÕÀÇ Á¤µµ¿¡ µû¶ó 1-3ÁÖ°£ÀÇ Àẹ±â¸¦ °ÅÃÄ ÀÌ½Ä ÆíÀº Å»¶ôÇÑ´Ù. ÀÌ½Ä °ÅºÎ ¹ÝÀÀµµ ºñÀÚ±âÀÇ Ç׿ø¼ºÀ» °¡Áø ¼¼Æ÷¸¦ Á¦°ÅÇϱâ À§ÇÑ ¸é¿ª ¹ÝÀÀÀÌ´Ù.
  • homograft rejection
    µ¿Á¾ ÀÌ½ÄÆí °ÅºÎ ¹ÝÀÀ
    µ¿ÀÏÇÑ Á¾ ³»¿¡¼­ÀÇ À̽Ŀ¡ ´ëÇÑ °ÅºÎ ¹ÝÀÀ.
  • immunologic rejection
    ¸é¿ªÇÐÀû °ÅºÎ
  • proximal tubular rejection
    ÀÎÁ¢ µµ°ü ºÀ¼â
  • rejection
    °ÅÀý, °ÅºÎ, ±â°¢, °ÅºÎ ¹ÝÀÀ
    ÀÌ½Ä Á¶Á÷¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀ. °úÀ× ¿¹¹Î¼º °ÅºÎ·Î ±âÁ¸ÀÇ Ç×ü¿¡ ÀÇÇÏ¿© ÀÌ½ÄÆí¿¡ ´ëÇÑ Áï½Ã ÀÀ´ä ¹ÝÀÀÀÌ ÀϾ ¼¶À¯¼Ò Ä§Âø, Ç÷¼ÒÆÇ ÀÀÁý, È£Áß±¸ ħÀ±ÀÌ ÀϾ¸ç °á±¹Àº À̽ÄÀÇ ½ÇÆÐ·Î ³¡³­´Ù.
  • acute and late normal tissue effects£¨Á¤»ó Á¶Á÷ ±Þ¼º ¿µÇ⣩

    acute angle

    ¿¹°¢
    Á÷°¢º¸´Ù ÀÛÀº °¢.
  • acute appendicitis£¨±Þ¼º Ãæ¼ö¿°£©

    acute arthritis

    ±Þ¼º °üÀý¿°
    ¿°Áõ°ú °¨¿°°ú ¿Ü»ó¿¡ ÀÇÇÏ¿© µ¿Åë, ¹ß¿­, ¹ßÀû, Á¾Ã¢ÀÌ ½ÉÇÑ °üÀý¿°.
  • acute mixed-lineage leukmia£¨±Þ¼º È¥ÇÕ-Á÷°è¼º ¹éÇ÷º´£©

    acute monocytic leukemia

    ±Þ¼º ´Ü±¸ ¹éÇ÷º´, ±Þ¼º ´Ü±¸¼º ¹éÇ÷º´
    ±Þ¼º ¹éÇ÷º´ÀÇ ÀÏÁ¾À̰í À¯¾à´Ü±¸°¡ ¹éÇ÷º´È­ÇÑ °ÍÀÌ´Ù. °ñ¼ö¿¡¼­ °ú¸³±¸°èÀÇ À¯¾à¼¼Æ÷¿Í ´Ü±¸°èÀÇ À¯¾à¼¼Æ÷°¡ È¥ÀçÇÏ´Â ¼ö°¡ ÀÖ°í ÀÌ °æ¿ì¿¡´Â ±Þ¼º °ñ¼ö´Ü±¸¼º ¹éÇ÷º´À̶ó°í ÇÑ´Ù.
  • cellular
    ¼¼Æ÷¼º, ¼¼Æ÷ÀÇ
  • cellular adhesiveness
    ¼¼Æ÷ ºÎÂø¼º
    ¼¼Æ÷°£¿¡ ¹°¸®ÀûÀÎ Àη ¶Ç´Â Á¢Ã˹°Ã¼ÀÇ Ç¥¸é°£¿¡ Á¸ÀçÇÏ´Â ºÐÀÚÀη¿¡ ÀÇÇÑ ºÎÂø¼º.
  • cellular antibody
    ¼¼Æ÷ Ç×ü
    ƯÀÌÀûÀÎ ¾Æ¹Ì³ë»ê ¹è¿­À» °¡Áø ¼¼Æ÷¼º ¸é¿ª ±Û·ÎºÒ¸° ºÐÀÚ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
acute cellular rejection Graft rejection which usually begins within 10 days after a graft has been transplanted into a genetically dissimilar host. Lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages which cause tissue damage.
See: primary rejection.
Synonym: acute rejection.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
acute kidney transplant rejection <radiology> Findings on ultrasound: globular enlargment of the kidney, swelling and hypoechogenicity of the medullary pyramids, indistinct cortico-medullary junction, foci in the renal cortex
(12 Dec 1998)
acute rejection Graft rejection which usually begins within 10 days after a graft has been transplanted into a genetically dissimilar host. Lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages which cause tissue damage.
See: primary rejection.
Synonym: acute rejection.
(05 Mar 2000)
accelerated rejection A transplant rejection manifested in less than three days.
(05 Mar 2000)
allograft rejection The rejection of tissue transplanted between two genetically different individuals of the same species. Rejection is caused by T lymphocytes responding to the foreign major histocompatibility complex of the graft.
Synonym: homograft.
(05 Mar 2000)
parental rejection Withholding of affection from or denial of attention to one's child.
Child's withholding of affection from its parent.
(05 Mar 2000)
rejection 1. <immunology, surgery> Usually used of grafts. Any process leading to the destruction or detachment of a graft or other specified structure.
2. <psychology> Non-acceptance, negative attitudes, hostility or excessive criticism of the individual which may precipitate feelings of rejection.
(12 Dec 1998)
graft rejection <haematology, immunology> When donated bone marrow infused during a bone marrow transplant is rejected by the patients body or does not take.
(16 Dec 1997)
chronic allograft rejection Immunologically mediated damage to the allograft, typically a kidney allograft, manifested by diffuse interstitial fibrosis glomerular changes, typically membranous and sclerotic in nature, as well as intimal fibrosis of the blood vessels with tubular atrophy and loss of tubular structures.
(05 Mar 2000)
chronic rejection A transplant rejection occurring after a few or many months, mainly from persisting serum antibody action.
(05 Mar 2000)
primary rejection A rejection occurring more than seven days after transplantation, mainly from a cellular immune response.
(05 Mar 2000)
second set rejection An accelerated rejection of a transplant that occurs when an individual has been previously sensitised to the graft.
(05 Mar 2000)
hyperacute rejection A rejection that usually develops in less than one hour from the implantation of a vascular graft, a form of antibody-mediated, usually irreversible damage to a transplanted organ, particularly the kidney, manifested predominantly by diffuse thrombotic lesions, usually confined to the organ itself and only rarely disseminated, for skin allograft rejection of this type, see white graft.
(05 Mar 2000)
first-set rejection Allograft transplantation between two organisms not previously sensitised to the graft tissue. Necrosis of the graft usually occurs within 10 days of transplantation.
(05 Mar 2000)
cellular 1. Relating to, derived from, or composed of cells.
2. Having numerous compartments or interstices.
Origin: L. Cellula, dim. Of cella, storeroom
(05 Mar 2000)
cellular biology <study> The study of cells. Implies the use of light or electron microscopic methods for the study of morphology.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute
    ³¯Ä«·Î¿î; °Ý·ÄÇÑ
  • acute
    ³¯Ä«·Î¿î;»ÏÁ·ÇÑ;¿¹¹ÎÇÑ;ºóÆ´¾ø´Â;°Ý·ÄÇÑ;±Þ¼ºÀÇ
  • cellular
    ¼¼Æ÷ÀÇ
  • cellular
    ¼¼Æ÷ÀÇ,¼¼Æ÷Áú(¸ð¾ç)ÀÇ;¼º±â°Ô § (¼ÅÃ÷µî);´Ù°øÁúÀÇ;ÅëÈ­Á¸(zone)½ÄÀÇ;¼¿ ¹æ½ÄÀÇ(À°»ó À̵¿ Åë½ÅÀÇ »õ·Î¿î ¹æ½Ä)
  • cellular engineering
    ¼¼Æ÷ °øÇÐ
  • rejection
    °ÅÀý
  • rejection
    ¹èÁ¦;Æó±â;°ÅÀý;°¢ÇÏ;ºÎ°á;±¸Åä;Æó±â¹°;°ÅºÎ(°ÅÀý)¹ÝÀÀ
  • rejection front
    °ÅºÎ Àü¼±(À̽º¶ó¿¤°ú ±³¼·.È­ÆòÀ» °ÅºÎÇÏ´Â ¾Æ¶øÁ¦±¹(Á¶Á÷)ÀÇ Àü¼±)
  • rejection slip
    (ÃâÆÇ»ç°¡ äÅà ¾Ê±â·Î ÇÑ ¿ø°í¿¡ ºÙ¿© º¸³»´Â)°ÅÀý ÂÊÁö;°ÅÀýÇ¥
  • rejection stmptom
    °ÅºÎ ¹ÝÀÀ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á